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Abstract
Chronic hepatitis B (HBV) and C (HCV) virus infections are the most important factors associated with hepatocellular carci-
noma (HCC), but tumor prognosis remains poor due to the lack of diagnostic biomarkers. In order to identify novel diagnostic 
markers and therapeutic targets, the gene expression profile associated with viral and non-viral HCC was assessed in 9 tumor 
samples by oligo-microarrays. The differentially expressed genes were examined using a z-score and KEGG pathway for the 
search of ontological biological processes. We selected a non-redundant set of 15 genes with the lowest P value for clustering 
samples into three groups using the non-supervised algorithm k-means. Fisher’s linear discriminant analysis was then applied 
in an exhaustive search of trios of genes that could be used to build classifiers for class distinction. Different transcriptional 
levels of genes were identified in HCC of different etiologies and from different HCC samples. When comparing HBV-HCC vs 
HCV-HCC, HBV-HCC/HCV-HCC vs non-viral (NV)-HCC, HBC-HCC vs NV-HCC, and HCV-HCC vs NV-HCC of the 58 non-
redundant differentially expressed genes, only 6 genes (IKBKβ, CREBBP, WNT10B, PRDX6, ITGAV, and IFNAR1) were found 
to be associated with hepatic carcinogenesis. By combining trios, classifiers could be generated, which correctly classified 100% 
of the samples. This expression profiling may provide a useful tool for research into the pathophysiology of HCC. A detailed 
understanding of how these distinct genes are involved in molecular pathways is of fundamental importance to the development 
of effective HCC chemoprevention and treatment.
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Hepatocellular carcinoma (HCC), the most important 
primary malignant tumor of the liver, is one of the human 
cancers clearly linked to viral infection (1). The major risk 
factors for HCC are chronic hepatitis B virus (HBV) infec-
tion, chronic hepatitis C virus (HCV) infection, prolonged 
dietary exposure to aflatoxin, alcoholic cirrhosis, and 
cirrhosis due to other causes such as hereditary hemo-
chromatosis (2). Some individuals who develop HCC are 
not infected with HCV or HBV, and do not have cirrhosis 
in the surrounding parenchyma. Although HCC mortality 
has significantly decreased with the development of new 
surgical techniques, about 60-100% of these patients 
ultimately suffer an HCC recurrence even after curative 
resection, and this has become the most important factor 
that limits the long-term survival of HCC patients. Shortage 
of organs and limited indications make transplantation a 
therapeutic method not frequently used for HCC (3). With 
advances in the understanding of tumor biology, interest 
in the molecular biomarkers of carcinogenesis has grown, 
both in terms of their prognostic significance and of their 
potential use as therapeutic targets (4). Several reports have 
provided information on multiple genetic changes such as 
chromosome aberrations, genetic alternations, and gene 
product abnormalities, which have been suggested to cause 
carcinoma of the liver (5-7). Considering the complexity of 
hepatocarcinogenesis, many genes are probably involved 
in the initiation and progression of this cancer, and compre-
hensive expression analysis using microarray technology 
has a great potential for the discovery of new genes involved 
in this process (8). Genome-wide gene expression analysis 
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by microarray offers a systematic approach to gaining com-
prehensive information regarding transcription profiles (9). 
Although these genomic approaches have yielded global 
gene expression profiles in HCC, new biomarkers useful 
for cancer staging, prediction of prognosis, and treatment 
selection must now be identified (8).
The present study was designed to identify new biomark-
ers for HCC using microarray analyses in order to identify 
genes differentially expressed in HCV- or HBV-associated 
HCC, and in non-viral HCC. 
Material and Methods
The study protocol (#633/06) was approved by the 
Ethics Committee of the School of Medicine, University 
of São Paulo.
Patients and tissues
We obtained liver tumor samples from 9 patients sub-
jected to hepatic resection or liver transplantation for HCC. 
Tumor tissue samples were either flash-frozen in liquid ni-
trogen or placed in ribonucleic acid (RNA) stabilization fluid 
(RNAlater®, Invitrogen, USA) and stored at -80°C. Of the 
9 patients, 3 were HBs antigen-positive (group HBV-HCC; 
samples B1, B2 and B3), 3 were HCV antibody-positive 
(group HCV-HCC; samples C1, C2 and C3), and 3 were 
double-negative for the HCV antibody and HBs antigen - 
non-viral HCC (group NV-HCC; samples N1, N2 and N3). 
For NV-HCC patients, aflatoxin exposure, alcoholic 
cirrhosis, cirrhosis due to other causes such as hereditary 
hemochromatosis and nonalcoholic steatohepatitis were 
excluded as causes of the carcinoma. No patients had other 
causes of hepatocellular injury, as confirmed by clinical and 
laboratory findings.
 
Microarray experiments
At the time of RNA extraction, diagnosis of HCC was 
confirmed by H&E staining. Total RNA was isolated and 
purified from frozen liver tissues using the RNeasy mini 
kit (Qiagen, Germany), according to the manufacturer 
protocol. The quality of total RNA samples was analyzed 
by inspection of 18S and 28S rRNA bands following aga-
rose gel electrophoresis. The concentrations of the RNA 
samples were quantified by measuring absorbance using 
a NanoDrop ND-1000 instrument (NanoDrop Technologies, 
USA). We utilized the CodeLink™ Human Whole Genome 
Bioarray (GE Healthcare Biosciences, UK) with ~57,000 
human transcripts represented in a single bioarray. Briefly, 
5 µg total RNA was first reverse transcribed to the single-
stranded cDNA and subsequent cRNA was synthesized 
using the CodeLink™ Expression Assay Kit (GE Healthcare 
Biosciences). The cRNA targets were prepared by in vitro 
transcription using a single labeled nucleotide, biotin-11-
UTP, in the in vitro reaction at a concentration of 1.25 mM. 
The concentration of unlabeled UTP was 3.75 mM, while 
the concentrations of GTP, ATP, and CTP were 5 mM in 
each case. The mixture was incubated at 37ºC overnight 
for 14 h. The labeled cRNA was then purified using the 
RNeasy™ mini kit (Qiagen) and subsequently fragmented 
in 1X fragmentation buffer (40 mM Tris-acetate, pH 7.9, 100 
mM KOAc, and 31.5 mM MgOAc) at 94ºC for 20 min. 
For hybridization, 10 µg fragmented cRNA in 260 µL 
hybridization solution was added to each bioarray and 
incubated for 18 h at 37ºC with shaking at 300 rpm in a 
shaking incubator. Immediately following hybridization, the 
bioarrays were washed and stained with Cy5™-streptavidin 
(GE Healthcare Biosciences) and scanned with a GenePix 
4000B Array Scanner (Axon Instruments, USA).
Data processing and statistical analysis
After image acquisition, the fluorescence intensity signal 
of each spot was corrected by subtracting fluorescence 
intensity background (spots with signal level less than or 
equal to background were identified and excluded from 
the analysis). Next, background-subtracted spot intensities 
were normalized by the global mean normalization proce-
dure (10). Replicate spots representing the same gene were 
identified, and average signal intensity was determined. 
Data analysis was performed using R (version 2.4.0), a 
free software environment for statistical computing and 
graphics (http://www.r-project.org), adapted to our needs. 
We searched our data for differentially expressed genes 
in the three groups (HCV-HCC, HBV-HCC and NV-HCC) 
using the Wilcoxon test. The level of significance was set 
at P < 0.01. Next, the differentially expressed genes were 
examined using a z-score and the Kyoto Encyclopedia of 
Genes and Genomes (KEGG) pathway (www.genome.
jp/kegg) for searching biological process ontologies. The 
z-score was derived by dividing the difference between 
the observed number of genes meeting the criterion in a 
specific Gene Ontology term and the expected number 
of genes based on the total number of genes in the array 
meeting the criterion, and standardized by dividing by the 
standard deviation of the observed number of genes under 
the hypergeometric distribution. A positive z-score indicates 
that more genes than expected fulfilled the criterion in a 
given group or pathway; therefore, the respective group or 
pathway is likely to be affected (11). For clustering, based 
on the expression profile we selected the non-redundant 
set of 15 genes [6 genes from each HCC group (18 genes) 
with 3 redundant genes being excluded], with the lowest 
P value for clustering samples into three groups using the 
non-supervised algorithm k-means. Once clusters were 
obtained, samples were organized hierarchically based on 
their correlation distances (12). To determine classifiers, 
we used Fisher’s linear discriminant analysis and carried 
out an exhaustive search of the entire dataset for trios of 
genes, such that data points representing signal intensity 
for all 3 genes for each sample were separated by a plane 
in a three-dimensional space. More precisely, for a given 
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group of genes, this linear classification method searches 
for linear combinations of their expressions with large ratios 
of between-group to within-group sum of squares (12). This 
maximal ratio of sum of squares, or its square root, which is 
denoted here by singular value decomposition, measures 
how well separated the three groups are. For the search of 
trios, the 9-sample dataset was split into three groups, and 
we performed an exhaustive search for the best classifica-
tion trios for each of the four comparisons of interest among 
HCV-HCC, HBV-HCC and NV-HCC samples. Trios were 
ranked according to their singular value decomposition and 
only trios with perfect classification were considered. 
Results
To identify differences in gene expression between 
HCC of different etiologies we compared mRNA samples 
prepared from the three groups, i.e., HBV-HCC, HCV-HCC 
and NV-HCC. Using the Wilcoxon test, we identified differ-
entially expressed genes for four comparisons: HBV-HCC vs 
HCV-HCC (1141 genes), HBV-HCC/HCV-HCC vs NV-HCC 
(2257 genes), HBV-HCC vs NV-HCC (1671 genes) and 
HCV-HCC vs NV-HCC (1584 genes). This set of filtered 
genes was stored and will be considered for further stud-
ies. Considering the multiplicity of gene selection, we used 
a second filtering criterion of at least a 2.0-fold change in 
expression, the Student t-test (P < 0.05) and the z-score 
parameter in order to classify the differentially expressed 
genes into known signaling pathways derived from the 
KEGG biological process. Genes were classified into several 
families according to their function after separating each 
HCC group. Twelve, 60, 76, and 49 genes were differentially 
expressed while 9, 43, 45, and 31 were non-redundant 
for the comparisons HBV-HCC vs HCV-HCC, HBV-HCC/
HCV-HCC vs NV-HCC, HBV-HCC vs NV-HCC, and HCV-
HCC vs NV-HCC, respectively, considering all selected 
pathways. Next, we selected only the non-redundant genes 
considering all comparisons. The functional categories and 
up-regulated or down-regulated genes in each comparison 
are summarized in Table 1.
Table 1. Biological process categories and differentially identified expressed genes for all comparisons.
KEGG pathways z-score UniGene ID  Symbol Fold differrence Up/Down
HBV-HCC vs HCV-HCC
Glycan structures-biosynthesis 1 2.02
Hs.8910 MAN1C1 2.23 Up
Hs.2134215 CHSY1 2.40 Up
Hs.443716 GALNTL5 2.06 Up
O-glycan biosynthesis 2.62
Hs.398039 GALNTL4 2.21 Up
Hs.411308 GALNTL2 0.37 Down
Valine, leucine and isoleucine degradation 2.09
Hs.81886 AUH 2.36 Up
Hs.356894 HSD17B4 3.18 Up
Hs.167531 MCCC2 2.57 Up
HBV-HCC/HCV-HCC vs NV-HCC
Amyotrophic lateral sclerosis 2.86
Hs.27669 ALS2 2.57 Up
Hs.458657 NEFM 0.41 Down
Hs.409223 SSR4 2.69 Up
Apoptosis 2.70
Hs.1519 PRKAR1B 0.41 Down
Hs.694 IL3 0.35 Down
Hs.460433 IL3RA 0.33 Down
Hs.401745 TNFRSF10A 0.11 Down
Butanoate metabolism 2.44
Hs.231829 GAD2 0.36 Down
Small cell lung cancer 2.45
Hs.413513 IKBKB 0.46 Down
Ubiquitin mediated proteolysis 3.59
- EDD1 0.07 Down
Hs.373992 RBX1 2.67 Up
Wnt signaling pathway 2.72
Hs.12248 CXX4 0.32 Down
Hs.270804 CREBBP 0.22 Down
Hs.3260 PSEN1 0.39 Down
Hs.356537 DAAM1 0.33 Down
Hs.91985 WNT10B 0.41 Down
Hs.12436 CAMK2G 2.27 Up
Hs.169294 TCF7 0.28 Down
Continued on next page
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A non-supervised clustering method was used to de-
termine whether the 15 genes with the lowest P value for 
each HCC group would be capable of grouping samples 
based on their expression profiles. Using the k-means 
algorithm (12), samples were grouped into three clusters 
on the basis of the expression profile of 15 genes that 
were non-redundant among the 6 genes with the lowest 
P value for all comparisons. The unsupervised hierarchi-
cal clustering analysis of all HCC samples was based on 
the similarity of the expression patterns for all genes. As 
shown in Figure 1, all HCC samples were fully clustered 
into three distinct groups HBV-HCC, HCV-HCC and NV-
Table 1 continued
KEGG pathways z-score UniGene ID Symbol Fold differrence Up/Down
HBV-HCC vs NV-HCC
Aminosugars metabolism 2.12
Hs.274424 NANS 3.16 Up
Bile acid biosynthesis 2.57
Hs.177687 AKR1C4 3.08 Up
- SOAT1 4.48 Up
Butanoate metabolism 3.43
Hs.120 PRDX6 3.34 Up
Glycan structures degradation 2.48
Hs.302018 HPSE2 0.33 Down
Hs.121494 SPAM1 0.19 Down
Glycosaminoglycan degradation 3.89
Hs.69293 HEXB 3.15 Up
Heparan sulfate biosynthesis 3.24
Hs.20894 NDST1 2.35 Up
Hs.20028 NDST3 0.43 Down
Hs.183006 GLCE 2.74 Up
Lysine degradation 2.16
Hs.160208 SETD7 3.85 Up
Hs.289848 DOT1L 0.44 Down
Small cell lung cancer 3.9
Hs.436873 ITGAV 2.58 Up
Toll-like receptor signaling pathway 2.64
Hs.181315 IFNAR1 2.44 Up
Hs.432466 TBK1 0.34 Down
- TICAM2 6.86 Up
Ubiquitin mediated proteolysis 3.59
Hs.413133 FZR1 2.93 Up
HCV-HCC vs NV-HCC
Calcium signaling pathway 2.44
Hs.512612 PHKG1 0.3 Down
Hs.25804 PLCE1 0.43 Down
Hs.144465 SLC8A1 0.45 Down
Hs.32945 GRM1 0.42 Down
Hs.272458 PPP3CA 2.14 Up
Hs.3022 TRHR 0.29 Down
Fructose and mannose metabolism 2.72
Hs.75835 PMM1 4.81 Up
Hs.404119 TSTA3 2.62 Up
Glyoxylate and dicarboxylate metabolism 2.11
Hs.4415543 MTHFD1L 2.84 Up
Hs.430606 CS 2.06 Up
Nicotinate and nicotinamide metabolism 4.11
Hs.58251 NMNAT1 2.49 Up
Hs.375214 SIRT2 3.44 Up
Hs.151135 FN3K 0.43 Down
Pyrimidine metabolism 4.68
Hs.67201 NT5C 2.59 Up
RNA polymerase 7.71
Hs.57813 ZNRD1 3.66 Up
Up- and down-regulation of non-redundant genes are defined as expression in HCC tissues considering HBV-HCC 
vs HCV-HCC, HBV-HCC/HCV-HCC vs NV-HCC, HBC-HCC vs NV-HCC, and HCV-HCC vs NV-HCC comparisons. 
HBV = hepatitis B virus; HCV = hepatitis C virus; HCC = hepatocellular carcinoma; NV = non-viral.
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HCC, according to the serological and histological analysis 
described in Material and Methods, corroborating their 
unique expression profile. 
In order to validate the hierarchical clustering analysis, 
we next applied another approach, this time using an ex-
haustive search for trios of genes, to precisely separate all 
tumor samples, with perfect class distinction on the basis of 
the expression signature of each individual sample. Using 
the signal intensity of all genes selected previously by the 
Wilcoxon test, we then applied the Fisher’s linear discrimi-
Figure 1. Clustering of the 9 hepatocellular carcinoma (HCC) samples according to the expression profile of 15 genes. Using the 
k-means algorithm, 9 HCC tissue samples representing the HBV-HCC (B1, B2, B3 samples), HCV-HCC (C1, C2, C3 samples) and 
NV-HCC (N1, N2, N3) groups were grouped into three clusters on the basis of the expression profile of the non-redundant set of 15 
genes representing the 6 genes with the lowest P value for each pair-wise comparison. The lines represent genes ordered according 
to their hierarchical distances. The red color denotes high expression and the green color denotes low expression compared with aver-
age expression among the nine samples. Within each cluster, samples were ordered on the basis of their correlation distances. HBV 
= hepatitis B virus; HCV = hepatitis C virus; NV = non-viral.
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nant analysis (12) and identified all possible trios of genes 
that correctly separate, without misclassifications, tissue 
samples in each of four possible comparisons: HBV-HCC vs 
HCV-HCC, HBV-HCC/HCV-HCC vs NV-HCC, HBV-HCC vs 
NV-HCC, and HCV-HCC vs NV-HCC. The number of trios 
found for each comparison was 9, 108, 19, and 14 trios for 
HBV-HCC vs HCV-HCC, HBV-HCC/HCV-HCC vs NV-HCC, 
HBV-HCC vs NV-HCC and HCV-HCC vs NV-HCC, respec-
tively, with perfect distinction (100%) of all samples. Figure 
2 and Table 2 show the examples of trios that can classify 
HBV-HCC vs HCV-HCC, HBV-HCC/HCV-HCC vs NV-HCC, 
HBV-HCC vs NV-HCC and HCV-HCC vs NV-HCC. 
Discussion
Oligo-microarray technology has been extensively 
applied to cancer research (13), and expression profil-
ing is being increasingly used for the distinction between 
physiological and disease states, as well as to distinguish 
between groups of disease samples for which the expres-
sion profile can discriminate between clinically or biologically 
similar entities (14). 
Although structural alterations in many cancer-related 
genes have been found in HCC (15), the high number of 
genes involved suggests that different etiological factors 
may affect different gene subsets within hepatocytes. Thus, 
distinct but related genetic pathways may be altered during 
hepatocarcinogenesis, possibly due to different initiators 
and promoters. Multiple studies linking hepatitis viruses 
and chemical carcinogens to hepatocarcinogenesis have 
provided clues for the understanding of this molecular 
system (16). Several reports have differentially identified 
Figure 2. Group classification by a trio of genes identified by Fisher’s linear discriminant analysis: A clear separation between (A) HBV-
HCC vs HCV-HCC, (B) HBV-HCC/HCV-HCC vs NV-HCC, (C) HCV-HCC vs NV-HCC, and (D) HBV-HCC vs NV-HCC is evident. Sam-
ples: B1, B2, B3 (HBV-HCC: blue), C1, C2, C3 (HCV-HCC: green) and N1, N2, N3 (NV-HCC: red). XPA = Xeroderma pigmentosum, 
complementation group A; PHF3 = PHD finger protein 3; ABCB1 = ATP-binding cassette, sub-family B, member 1; MAPRE2 = microtu-
bule associated protein, member 2; CLCN4 = chloride channel 4; TAAR3 = trace amine receptor 3; CXCL14 = chemokine (C-X-C motif) 
ligand 14; SLC35B2 = solute carrier family 35, member 2; SUV39H2 = suppressor of variegation 3-9, homolog 2; SLC15A3 = solute 
carrier family 15, member 3. HBV = hepatitis B virus; HCV = hepatitis C virus; HCC = hepatocellular carcinoma; NV = non-viral.
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expressed genes in HCC using oligo-microarrays (17,18). 
Although genomic approaches have yielded global gene 
expression profiles in HCC and have identified a number 
of candidate genes as biomarkers useful for cancer stag-
ing, the prediction of prognosis and treatment selection (8) 
remain unclear across all subsets of HCC (19). 
We first analyzed our microarray platform by search-
ing for differentially expressed genes in the three groups 
of HCC. We demonstrated that expression profiling can 
identify genes that differentiate HBV-HCC, HCV-HCC and 
NV-HCC. Of the 58 non-redundant differentially expressed 
genes (Table 1) considering HBV-HCC vs HCV-HCC, HBV-
HCC/HCV-HCC vs NV-HCC, HBC-HCC vs NV-HCC, and 
HCV-HCC vs NV-HCC comparisons, only 6 genes (IKBKβ, 
CREBBP, WNT10B, PRDX6, ITGAV, and IFNAR1) are 
involved in hepatic carcinogenesis. These genes have 
also been described in experimental studies of hepatocar-
cinogenesis (20-28).
IkB kinase β (IKBKβ) is required for activation of NF-kB, 
a transcription factor that regulates liver inflammation and 
protection from injury. Koch et al. (20) found that IKBKβ 
deletion conferred direct growth advantages to hepato-
cytes and enhanced cell proliferation. Both advantages 
implicate a growth-suppressor role of IKBKβ under condi-
tions of induced hepatotoxicity and hepatocarcinogenesis. 
Therapies may target IKBKβ in Kupffer cells to prevent 
hepatic inflammation, hepatocyte proliferation, and hepatic 
carcinogenesis (21). 
Cyclic AMP responsive element-binding protein 
(CREBBP) is a transcriptional co-activator that plays an 
essential role in the liver by regulating gene expression 
and different processes such as gluconeogenesis, lipid 
metabolism, and cell proliferation (22). Abramovitch et al. 
(23) demonstrated both in vitro and in vivo that CREBBP 
involves resistance to apoptosis and plays an important 
role in HCC tumor progression. 
The WNT10B gene is a member of the Wnt family, 
which plays crucial roles in normal development and neo-
plastic transformation. WNT10B expression seems to be 
a specific event in cancer because normal liver does not 
show detectable expression of WNT10B. Yoshikawa et al. 
(24) demonstrated that WNT10B can be silenced by DNA 
methylation.
PRDX6 is a member of the PRDX family, associated 
Table 2. Examples of trios of genes considering HBV-HCC vs HCV-HCC, HBV-HCC/HCV-HCC vs NV-HCC, HBC-HCC vs NV-HCC, 
and HCV-HCC vs NV-HCC comparisons.
Comparisons Trios
Gene 1 Gene 2 Gene 3
Hs Symbol Hs Symbol Hs Symbol
HBV-HCC vs HCV-HCC
374950 MT1X 324746 AHSG 422855 ADH1A
324746 AHSG 446588 RPS13 117367 SLC22A1
446588 RPS13 10862 AK3L1 497571 SERPINA3
10862 AK3L1 497571 SERPINA3 21162 RTBDN
389700 MGST1 497571 SERPINA3 107 FGL1
HBV-HCC/HCV-HCC vs NV-HCC
324746 AHSG 374596 TPT1 1955 SAA2
356502 RPLP1 374596 TPT1 2795 LDHA
374596 TPT1 177530 ATP5E 1955 SAA2
177530 ATP5E 1955 SAA2 512676 RPS25
1955 SAA2 512676 RPS25 2795 LDHA
HBV-HCC vs NV-HCC
324746 AHSG 427202 TTR 374950 MT1X
427202 TTR 374950 MT1X 356502 RPLP1
380135 FABP1 374950 MT1X 389700 MGST1
497571 SERPINA3 374950 MT1X 356502 RPLP1
HCV-HCC vs NV-HCC
324746 AHSG 356502 RPLP1 439552 EEF1A1
356502 RPLP1 439552 EEF1A1 381172 RPL41
439552 EEF1A1 381172 RPL41 177530 ATP5E
374596 TPT1 433529 RPS11 1955 SAA2
433529 RPS11 1955 SAA2 512676 RPS25
HBV = hepatitis B virus; HCV = hepatitis C virus; HCC = hepatocellular carcinoma; NV = non-viral.
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we next constructed a cluster where samples were orga-
nized hierarchically (Figure 1). Based on their correlation 
distances, the samples were perfectly separated.
Subsequently, in order to confirm our differentially ex-
pressed genes between groups, Fisher’s linear discriminant 
analysis was applied. We performed an exhaustive search 
of trios of genes that could be used to build classifiers for 
distinction between viral and non-viral HCC. There are few 
reports in the literature concerning this approach. Meire-
les et al. (29) determined the expression profile in tissue 
samples representing normal gastric mucosa, as well as 
gastritis, intestinal metaplasia, and adenocarcinoma of the 
stomach. Using Fisher’s linear discriminant analysis, these 
investigators identified a series of molecular classifiers that 
could distinguish between cancer and non-cancer samples. 
They also identified a series of intestinal metaplasias whose 
gene expression profile resembled that of adenocarcinoma. 
Stolf et al. (30) searched for expression signatures of in-
dividual samples of adenomas and follicular carcinomas 
that could be used as molecular classifiers for the precise 
classification of malignant and non-malignant lesions. In 
our study, we found a strong correlation between data from 
classifiers and from cluster analysis. All samples that were 
classified by the trios were grouped into the hierarchical 
cluster. This is the first study that focuses on a search for 
genes that could be used for the construction of molecular 
classifiers. It is now imperative to apply these classifiers to 
a large set of samples. 
We identified differentially expressed genes in HCC of 
different etiologies, and this expression profiling may pro-
vide useful clues for pathophysiological research into HCC. 
Molecular stratification of individual HCC into genetically 
homogeneous subclasses can be of help by offering an 
opportunity for developing optimal therapeutic agents for 
various HCC based on their distinctive genomic types. 
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